BioMarin Pharmaceutical Inc.’s expected high price tag for its gene therapy for hemophilia A, and the fact that data has suggested Roctavian’s effect may have declined over time, was likely prompting some tough questions from payers even before the US Food and Drug Administration decided to delay a decision on approval.
In a move that surprised many stakeholders, FDA sent a complete response letter to the company two days before its...







